No body including instutions is going to hold on a stock which has no drug pipeline which can be developed into promissing commercial products. NBIX's institution holders are not smart as you thought, many of them sold its shares at $2 to $4 range.
When a successful UCN2 phase II trai result is anounced, this stock will move up ward quickly.